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Effects of moderate Sicilian red wine consumption
on inflammatory biomarkers of atherosclerosis
G Avellone, V Di Garbo, D Campisi, R De Simone, G Raneli, R Scaglione and G Licata
Institute of Clinical Medicine, University of Palermo, Palermo, Italy
Objective: The aim of the study is to evaluate the effect of moderate Sicilian red wine consumption on cardiovascular risk factors
and, in particular, on some inflammatory biomarkers.
Methods: A total of 48 subjects of both sexes who were nondrinkers or rare drinkers of moderate red wine were selected and
randomly subdivided into two groups assigned to receive with a crossover design a Sicilian red wine (Nero d’Avola or Etna
Torrepalino) during meals: Group A (n¼24), in whom the diet was supplemented for 4 weeks with 250 ml/day of red wine,
followed by 4 weeks when they returned to their usual wine intake; and Group B (n¼ 24), in whom the usual wine intake was
maintained for 4 weeks, followed by 4 weeks when the diet was supplemented with 250 ml/day of red wine. The following were
values measured in all tests: blood glucose, total and HDL-cholesterol and triglycerides, LDL-cholesterol, LDL/HDL ratio,
apolipoproteins A1 and B, Lp(a), plasma C-reactive protein, TGFb1, D-Dimer, Factor VII , PAI Ag, t-PA Ag, fibrinogen, oxidized
LDL Ab, total plasma antioxidant capacity.
Results: At the end of the red wine intake period, LDL/HDL, fibrinogen, factor VII, plasma C-reactive protein and oxidized LDL
Ab were significantly decreased, while HDL-C, Apo A1,TGFb1, t-PA, PAI and total plasma antioxidant capacity were significantly
increased.
Conclusions: Our results show a positive effect of two Sicilian red wines on many risk factors and on some inflammatory
biomarkers, suggesting that a moderate consumption of red wine in the adult population is a positive component of the
Mediterranean diet.
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Introduction
Wine is an alcoholic drink that in the Mediterranean culture
has not only long played an important part in meals but
also has a key role (together with olive oil intake and
considerable vegetable consumption) in the protective
effects of the Mediterranean diet on cardiovascular diseases
(Avellone et al., 2003; Carluccio et al., 2003). The complex
relationship between alcohol consumption and human
health has been widely studied in recent years. Recent
studies, while confirming the adverse effects of excessive
alcohol consumption, have demonstrated that moderate
daily wine consumption can reduce the incidence of
coronary artery diseases (CAD) and, more generally, cardio-
vascular diseases (Rimm et al., 1991; Renaud and de Lorgeril,
1994).
One of the greatest stimuli for the scientific study of wine
consumption has been the discovery of the so-called ‘French
paradox’. Clinical evidence originating from epidemiological
studies on cardiovascular diseases and food habits indicates a
linear correlation between saturated fatty acid dietary intake
and the incidence of CAD, with a decreasing trend from
countries in northern Europe to the Mediterranean area
(Renaud and de Lorgeril, 1994). However, an anomaly has
been pointed out in this trend, because in France, despite the
high saturated fat dietary intake, there is a lower incidence of
CAD, which appears to be related to alcohol intake and in
particular to red wine intake (Artaud-Wild et al., 1993; Kondo
et al., 1994).
Among wines, red wine appears to have a more protective
effect, as it contains antioxidant substances liberated from
the grape skin and seeds. In the making of white wine, these
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are immediately removed from the must, which is left to
ferment without the solid parts of the grapes. The chemical
analysis of wine makes it possible to identify certain
substances considered to be responsible for this protective
effect: polyphenols, in particular, including epicatechin and
quercetin and, to a lesser extent, trans-resveratrol (Frankel
et al., 1993a, b; Hertog et al., 1993; Pace-Asciak et al., 1995).
On the basis of these considerations, and in relation to
Sicilian wines and vine species (Gebbia et al., 2003), we
hypothesized that Sicilian red wines might also play a
protective role in the prevention of CAD. The protective
mechanisms would appear to be independent of the effect of
equivalent aliquots of the wine’s alcohol content but instead
to be due to particular features of the vine species and to the
polyphenol content (flavonoids, trans-resveratrol and poly-
meric tannins), the concentration of which is closely related
to the wine-making technique (Kondo et al., 1994). It is
known that cytokines and acute phase proteins play an
important role in modulating inflammatory and prolifera-
tive responses, including atherosclerosis. Transforming
growth factor-beta 1 (TGFb1) and high-sensitivity C-reactive
protein (hs-CRP) are major anti-inflammatory and proin-
flammatory markers, respectively. For the above reasons, we
take into consideration the effects on some cardiovascular
risk factors and, in particular, on inflammatory biomarkers
(TGFb1 and hs-CRP) induced by the intake of 250 ml per day
of a Sicilian red wine (Nero d’Avola or Etna Torrepalino)
during meals.
Methods
A total of 48 individuals, all apparently healthy, aged
between 35 and 65 years (average age 43.6710.6 years, male
subjects¼28 and female subjects¼20, body mass index
(BMI)¼23.672.5 kg/m2), nondrinkers or rare moderate wine
drinkers (o250 ml per week), attending the lipid and
thrombosis Centre of the Internal Medicine Department of
the University of Palermo, Palermo, Italy, were enrolled.
Obese persons (BMI 430 kg/m2) and those practising active
sports activity or with incorrect food habits were excluded.
This evaluation was performed by a food interview by
dietitians and by the establishment of food, energy and
nutrient intake by means of a weekly diary (7 days food
record). None of the individuals had a history of acute or
chronic CAD, severe liver or kidney diseases, alterations of
glycaemic (with blood glucose 4110 mg/%) or lipid meta-
bolism (with total cholesterol 4240 mg/% or triglycerides
4200 mg/%) or current therapy with antiplatelet, anti-
coagulant or hypolipidaemic drugs. The women were not
on oral contraceptives. All persons with high plasma homo-
cysteine levels or with vitamin B12 and/or folate deficiency,
heavy smokers or drinkers (two or more drinks per week),
were also excluded. All participants gave their informed oral
consent to enter the study before commencement of the
investigation (according to the Helsinki declaration).
All enrolled subjects, after a clinical and instrumental
examination (blood pressure, standard and during exercise
E.C.G. monitoring, extracranial carotid arteries and peri-
pheral arteries by B-mode Duplex scanning system evalua-
tion), were randomly subdivided into two groups and were
assigned to receive, with a crossover design, one of two types
of a Sicilian red wine (Nero d’Avola-Rallo, 1999 or Etna
Torrepalino-Solicchiata, 1999) supplied by the Sicilian
Agricultural Development Bureau: Group A (n¼24), whose
diet was supplemented for 4 weeks with 250 ml/day of a red
wine (12 with Nero d’Avola and 12 with Etna Torrepalino)
during meals and for the following 4 weeks, when they
returned to their usual wine intake (i.e., no drink or only
occasional wine) and Group B (n¼24), who for 4 weeks
maintained their usual wine intake (i.e., no drink or only
occasional wine only) and whose diet for the following
4 weeks was supplemented with 250 ml/day of red wine
(12 with Nero d’Avola and 12 with Etna Torrepalino) during
meals.
The following parameters were determined: blood glucose,
total cholesterol and triglycerides (by enzyme kit methods-
Boehringer Mannheim), HDL-cholesterol (HDL-C, by
selective precipitation with dextran-magnesium chloride),
LDL-cholesterol (LDL-C, by calculation with the Friedewald
formula), LDL/HDL ratio, apolypoproteins A1 e B (Apo A1
and B, by nephelometric assay, Dade Behring, Marburg,
Germany), lipoprotein(a) (Lp(a), ELISA, Technoclone, Vienna,
Austria), CRP (High Sensitivity, Dade Behring), oxidized LDL
antibody (ox-LDL Ab, ELISA), total antioxidant capacity
(TAC) of blood plasma (estimated using the ferric reducing
ability of plasma (FRAP) method) (Benzie and Strain, 1996),
TGFb1 (ELISA, E&D Systems, Minneapolis, MN, USA),
D-Dimer (Turbiquant, Dade Behring), factor VII (F VII,
coagulant activity, Dade Behring), plasminogen activator
inhibitor antigen (PAI Ag, ELISA), tissue plasminogen
activator antigen (t-PA Ag, ELISA) and fibrinogen (coagulant
activity). Blood was drawn between 08:00 and 09:00 from an
antecubital vein, after overnight fasting and a 24 h absti-
nence from smoking, alcohol and coffee, using a 1.2 mm
siliconized needle without or with minimal stasis by the
two-syringe technique. Blood samples for the measurements
of haemostatic tests, after discarding the first 3–4 ml of
blood, were collected in polypropylene tubes containing
one-tenth final volume of 3.8% sodium citrate, kept on
crushed ice until centrifugation (41C, 2500 g, 15 min), and
plasma was stored in small aliquots at 701C until use.
Laboratory tests were determined at times: 15 days and 0
(to control the inclusion and/or exclusion criteria validity),
þ4 weeks and þ8 weeks (to check the possible effects of
food modifications on the parameters examined).
Adherence was supervised by dieticians by means of a
weekly diary and a food use questionnaire performed in
personal conversation at times: 15 days and 0 (to control
the inclusion and/or exclusion criteria validity), þ4 weeks
and þ8 weeks (to check adhesion to the prescribed dietetic
programme).
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At baseline all subjects followed the typical ‘Mediterranean
diet’ (protein 1471.1, carbohydrate 5672.3, fat 3071.5% of
energy) with high dietary fibre intake (2972.2 g/die),
polyunsaturated/saturated (P/S) (0.6870.1) and monounsa-
turated/saturated (M/S) (1.9870.25) fatty acid ratios and low
cholesterol intake (224.6713.3 mg/die) and omega-6/
omega-3 fatty acid ratio (6.1671.27).
All values were expressed as mean and standard deviation
(s.d.). Statistical analysis was carried out by Student’s t-test
for unpaired data with normal distribution according to the
Kolmogorov–Smirnov test. The nonparametric Mann–Whitney
U-test was used for data not normally distributed. The
relationships between TGFb1 and the other parameters were
analysed by nonparametric linear regression with Kendall’s
rank correlation coefficient. Data are expressed as mean7s.d.
A value of Po0.05 was accepted as statistically significant.
Backward multivariate analyses (GraphPad Software, San
Diego, CA, USA) were performed to assess the predictors of
TGFb1 levels.
Results
Lipid parameters after wine supplementation
At the end of addition to the diet of Sicilian red wine
(Table 1), HDL-C (Po0. 01) and Apo A1 (Po0.05) both in
group A (at time þ4 weeks) and in group B (at time þ8
weeks) were significantly increased (Table 1). No significant
change was observed in the other lipid parameters, except
for LDL/HDL ratio, in which there is a significant reduction
(Po0.05) both in group A (at time þ4 weeks) and in group B
(at time þ8 weeks) after red wine intake.
Other variables after wine supplementation
The effects of two Sicilian red wines (Nero D’Avola and Etna
Torrepalino) on coagulative, fibrinolytic and inflammatory
parameters are shown in Table 2.
The addition of wine to the diet induced both in group A
(at time þ4 weeks) and in group B (at time þ8 weeks) a
significant reduction of fibrinogen (Po0.01), F VII (Po0.01),
CRP (Po0.005) and ox-LDL Ab (Po0.05) levels and a
significant increase of t-PA (Po0.005), PAI (Po0.005) and
TAC (Po0.005) levels. No significant change was observed in
D-dimer levels.
During the study (data not shown) no significant change
in body weight, blood pressure or diet was found in either
group – these data were well-balanced throughout the period
of study (carbohydrates, 56%; fats, 30%; proteins, 14%)
(except for an increase, þ7%, in total energy intake during
wine supplementation).
Associations between TGFb1 and other variables
In the multivariate analysis, only age (b¼0.5898,
Po0.0008), blood glucose (b¼0.4213, Po0.0143), Ox-
LDLAb (b¼2.064, Po0.0019) and red wine consumption
(b¼8.687, Po0.0020) were an independent predictor
of variation of TGFb1 levels. The percentage of variance
in TGFb1 shown by the model is 84.78 (R2¼ 0.8478–
Po0.0001).
Discussion
Many recent studies have focused on the well-known
relationship between alcohol consumption and cardio-
vascular risk. A reduced cardiovascular mortality in subjects
with moderate daily alcohol consumption compared to that
of nondrinkers with or without a history of CAD has been
observed (Muntwyler et al., 1998). In the same study the
evaluation of all-cause mortality found between alcohol
consumption and cardiovascular events not a linear but a
U-shaped correlation, with the lowest mortality in subjects
with moderate alcohol consumption (about one drink per
day). Albert et al. (1999) observed a reduction in the risk of
Table 1 Changes in metabolic parameters induced by Sicilian red wine
0 þ 4 weeks þ8 weeks
Blood glucose (mg%)
A 100.273.5 101.073.4 100.773.6
B 101.773.4 100.673.3 101.173.6
Triglycerides (mg%)
A 130.4752.5 121.8748.8 130.5752.7
B 131.6751.5 130.9752.9 141.0749.6
Cholesterol (mg%)
A 217.7728.6 207.9725.3 219.0727.5
B 216.1728.0 217.2727.3 208.8725.7
HDL-C (mg%)
A 44.173.4 48.673.1** 44.073.2
B 44.773.6 44.873.5 48.573.5##
LDL-C (mg%)
A 147.4726.2 136.5722.7 148.0726.6
B 145.9725.6 146.5726.5 136.7723.0
LDL-C/HDL-C
A 3.3470.49 2.8670.37** 3.3670.49
B 3.2670.50 3.2670.49 2.8870.36##
APO A1 (mg%)
A 103.0721.4 115.0717.7* 103.5719.7
B 104.5721.6 104.4721.6 115.4715.0#
APO B (mg%)
A 97.7728.1 98.2719.9 98.4723.5
B 96.9726.0 97.3724.2 99.0718.7
Lp(a) (mg%)
A 26.5712.8 20.9713.7 26.8713.1
B 24.7711.2 25.9710.3 20.9711.6
*Po0.05 and **Po0.01 vs time 0; #Po 0.05 and ##Po0.01 vs þ4 weeks.
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sudden cardiac death correlated to alcohol consumption,
also with a U-shaped relationship. The incidence of sudden
cardiac death is, in fact, high in nondrinkers, decreases in
drinkers (about one drink per day) and increases in drinkers
of two or more drinks per day. Several recent studies,
surveying wine, beer and spirits drinkers separately, have
found a reduction in the risk of developing a myocardial
infarction (Gaziano et al., 1999) or an ictus (Sacco et al.,
1999) of about 50% in habitual drinkers of any type of
alcoholic drink.
Some favourable effects of moderate alcohol consumption
in the prevention of CAD have been confirmed by
epidemiological and experimental data. It has been known
for some time that alcohol intake is positively associated
with cholesterol levels bound to HDL, which is known
to be an antiatherogenic lipoprotein fraction. The correla-
tion between these two parameters is substantially linear,
going from nondrinkers to heavy alcohol drinkers
(more than six drinks per day) (Lacko et al., 2000). Apo A1
levels, the major HDL apolipoproteins, also respond favour-
ably to a daily intake of alcohol (De Oliveira e Silva et al.,
2000).
The results of our study on lipoprotein fractions are
consistent with various data in the literature. Both the
Sicilian wines in question caused a significant increase in
HDL-C and Apo A1 levels and a nonsignificant reduction in
total cholesterol and LDL-C levels. This led to a significant
reduction in the LDL-C/HDL-C ratio, which is an important
marker of cardiovascular risk (Assmann et al., 1998).
Alcohol consumption affects not only certain lipid para-
meters but also some mechanisms of blood coagulation and
thrombosis. Regarding the coagulative pattern, both wines
caused a reduction in fibrinogen and FVII levels, which are
today considered markers of cardiovascular risk (Meade et al.,
1986). Regarding fibrinogen, which is an independent risk
factor of cardiovascular diseases, Mennen et al. (1999)
demonstrated an inverse correlation in females between
alcohol consumption and fibrinogen levels, while in males
the correlation was U-shape, that is, with the lowest
fibrinogen levels between 20 and 60 g of alcohol consump-
tion – these had the largest cardiovascular protection .
A moderate dose of alcohol is also able to favourably affect
platelet aggregation, while a high dose of alcohol carries
out an action that favours a thrombus. Thromboxane
urinary excretion increases significantly after a heavy
evening intake of alcohol (Numminen et al., 2000).
Our study supplies a possible explanation for the reduction
of cardiovascular events induced by moderate alcohol
consumption. It should also be noted that significant
differences in platelet aggregation are reported between
red and white wine, with a smaller platelet aggregation to
collagen in subjects drinking red wine, probably because of
the different polyphenol content in the two types of wine
(Pignatelli et al., 2002). This result is confirmed by De Lange
et al. (2003) who analysed the direct effect of alcohol, red
wine and red wine polyphenolic extract on ADP-induced
platelet aggregation. Only red wine polyphenolic extract has
an inhibitory effect on platelet aggregation, while alcohol
itself does not have a direct inhibitory effect within a range
of up to 0.24%.
Regarding the fibrinolytic pattern, it is known that wine
has a positive action. The fibrinolytic system plays a key role
in the regulation of haemostasis and thrombosis. Deficient
fibrinolysis is often due to either reduced t-PA activity or
increased circulating levels of PAI. In the study conducted by
Ridker et al. (1994) a linear correlation was found between
t-PA levels and alcohol consumption. Passing from daily
drinkers of any alcoholic drink to weekly or monthly
drinkers, and then to nondrinkers, t-PA concentrations
decreased by 30%, inducing a larger inclination for thrombus
stabilization and therefore for thrombosis. In our study, the
two wines led to an increase both in t-PA and in PAI levels. It
is known that, paradoxically, t-PA increase is a risk factor for
cardiovascular events. However, as the increase in t-PA levels
(þ80.8 and 74.9% after Nero D’Avola or Etna Torrepalino
intake, respectively) was more marked than the increase in
Table 2 Changes in coagulative-fibrinolytic and inflammatory para-
meters induced by Sicilian red intake
0 þ4 weeks þ8 weeks
Fibrinogen (mg%)
A 336.2771.3 254.4749.6** 338.5765.9
B 340.1772.1 340.2770.7 259.5748.5##
D-Dimer (mg%)
A 371.67148.0 386.07110.4 372.17149.0
B 369.87148.1 371.27154.0 385.47116.1
Factor VII (%)
A 107.1714.0 93.9712.4* 108.2715.5
B 108.6714.2 109.1713.0 94.3711.2#
t-PA (ng/ml)
A 5.572.3 9.872.4** 5.472.4
B 5.672.5 5.572.5 9.772.6##
PAI (ng/ml)
A 51.0717.7 78.9718.1** 61.4720.3
B 50.0713.7 52.9714.1 81.9717.3##
TGFb1(ng/ml)
A 32.979.2 42.979.7** 33.378.6
B 33.578.9 32.778.8 44.179.5##
hsCRP (mg/l)
A 1.6870.67 0.7970.67** 1.6970.65
B 1.6470.59 1.6570.63 0.7870.71##
Ab-LDLox (mg%)
A 251.4763.9 209.1745.4* 253.4761.8
B 247.3767.6 249.0767.0 205.9743.8#
TAC (mmol/l)
A 0.99070.028 1.30270.044** 1.01070.026
B 1.00970.028 1.00570.029 1.27770.044##
*Po 0.01 and **Po 0.005 vs time 0; #Po 0.01 and ##Po 0.005 vsþ4 weeks.
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PAI levels (þ51.6 and 59.5%, respectively), the result was
that there was a global activation of fibrinolysis. This can be
explained by the occurrence of reduced inactive t-PA/PAI
complexes in blood resulting increased free t-PA levels
(Ridker et al., 1994). The activation of fibrinolytic activity
was confirmed by a significant reduction of fibrinogen levels,
an acute phase reactant, and by an increase (not statistically
significant) of D-dimer levels.
Together with the properties of ethylic alcohol, it is
widely known that the protective role of wine is largely
due to its nonalcohol component, that is, to nonvitaminic
phenolic compounds with proven antioxidant activity.
Several experimental studies in vitro have demonstrated that
the phenolic compounds of wine can modulate resistance
to human LDL oxidation; it is also widely known that LDL
oxidation is one of the pathogenetic bases of atherosclerotic
vascular disease (Hertog et al., 1993). In previous studies,
higher levels of ox-LDL Ab have been reported to increase
the risk of CAD, while the antioxidative properties of red
wine have been invoked to explain the paradox of lower
cardiovascular mortality, in spite of high-fat intake, in the
French population. However, the distribution of ox-LDL Ab
in the unselected population and its relationship with red
wine consumption are unknown. In vivo, in the study of
Cartron et al. (2003) the protective effect of red wine, white
wine and French champagne appears to be due to lipid
parameter modifications and not to plasma antioxidant
characteristics, which showed significant modifications
either after a single intake or after a long-term daily intake
administration (3 weeks). In our study, in contrast with these
results, a reduction in ox-LDL Ab and an increase in TAC
were observed after only 4 weeks of daily red wine intake.
This significant result, observed in both the Sicilian wines
(rich in polyphenols), may reflect a protective role in the
pathogenetic mechanisms of atherosclerotic vascular dis-
ease. Our finding is confirmed by Di Bari et al. (2003) who
observed a significant inverse relationship between ox-LDL-Ab
and daily wine intake, possibly because of its antioxidant
properties.
In addition to and independently of its antioxidant
effects, consumption of polyphenol-rich food, such as
red wine, enhances the production of vasodilating factors
and inhibits the synthesis of vasoconstrictor factors (Stoclet
et al., 2004). It must be emphasized that both the Sicilian
red wines showed a reduction in hs-CRP and an increase in
TGFb eta1 levels. CRP is an acute phase protein that
among the markers of inflammation is today considered
an independent risk factor in the development of thrombo-
embolic complications (Di Garbo et al., 2000). For
several years now, inflammation has been identified with a
crucial phase in the early development and growth of
atherosclerotic lesions, because – apart from favouring the
development of platelets – it may cause their rupture (Imfof
et al., 2001; Sierksma et al., 2002). It is well known that
platelet rupture is crucial in the development of acute
coronary syndromes.
TGFb1 is a multifunctional cytokine that inhibits athero-
matous process by inhibiting both the migration and the
proliferation of smooth muscle cells and macrophages and
by protecting endothelial function. It is secreted in a latent
inactive form that is activated proteolytically by plasmin. In
turn, plasmin is produced from plasminogen by t-PA, the
production of which is blocked by competitive inhibition
fron Lp(a) and PAI-1 (Stefoni et al., 2002). Tashiro et al.
(2002) suggested that plasma concentrations of TGF-b1
decreased in patients with CAD and might have prognostic
significance, considering that patients with low levels of
TGF-b1 had a significantly poor prognosis in terms of
survival.
To the best of our knowledge, this is the first study to
make a systematic analysis of the potential determinants of
TGF-b1 levels. The results of multivariate analyses demon-
strated significant inverse correlations between TGFb1
and age, blood glucose and Ox-LDL Ab levels, which are all
related to endothelial dysfunction. In addition, only
red wine consumption is significantly associated with an
increase in TGFb1 levels. The low TGFb1 levels
could therefore be hypothetically related to subclinical
endothelial damage, suggesting that the improvement
of endothelial function plays the key role among the
numerous plausible mechanisms by which red wine
may confer cardiovascular protection, possibly through an
anti-inflammatory effect. This mechanism is in keeping
with previous studies in which tumour necrosis factor alpha
(TNF-alpha)-induced adhesion of monocytes to endothelial
cells is virtually abolished after red wine consumption
(with high polyphenolic content) but is only partially
reduced after gin consumption (with low polyphenolic
content) (Badia et al., 2004). This effect may be due to the
downregulation of adhesion molecules on the monocyte
surface (Estruch et al., 2004). Nevertheless, the role of TGFb1
in atherosclerosis needs further evaluation and correlation
with other known risk factors by means of longer prospective
controlled studies.
Conclusion
Although this is a short-term study and the sample
is not very wide, our results show the positive effect
of the two Sicilian red wines taken into consideration on
numerous cardiovascular risk factors and certain inflamma-
tory biomarkers. This anti-inflammatory action of red
wine may help to explain, at least in part, the link
between moderate alcohol consumption and lower cardio-
vascular disease risk, suggesting that a moderate red
wine intake is to be encouraged in the adult popula-
tion (not suffering from liver diseases or in whom
alcohol intake is otherwise inadvisable) as an integrative
part of the Mediterranean diet (Mezzano et al., 2001;
de Lorgeril et al., 2002; Goldfinger, 2003; Avellone et al.,
2004).
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